EUVIMEDSkopri EUVIMED
Open access · CC BY-NC-ND 4.0

Unexpected [18F]-fluciclovine hyperuptake in radiation necrosis after proton therapy: illustrative case

Kazuaki Kamata, Seisuke Tanigawa iD, Yasuhiro Takeuchi, Takanari Okamoto iD, Ichita Taniyama iD, Hayato Takeuchi, Takumi Yamanaka iD, Norihiro Aibe, Sachimi Yamada iD, Kei Yamada, Naoya Hashimoto

Journal of Neurosurgery: Case Lessons · 2026-05-25 · 11 (21)

DOI: 10.3171/case26222 ↗

At a glance

Journal article in Journal of Neurosurgery: Case Lessons, published on 2026-05-25. Written by Kazuaki Kamata and 10 co-authors. Institution: Department of Neurosurgery, Kyoto Prefectural University of Medicine, Kyoto. 46 references. The full text is freely available (open access, CC BY-NC-ND 4.0).

AstrattSubjectsDettalji biblijografiċiCiteRelated studies

Abstract (original language)

BACKGROUND [ 18 F]-Fluciclovine PET is increasingly used for visualizing malignant gliomas and delineating tumor infiltration. More recently, its utility has been reported in differentiating tumor recurrence from radiation necrosis (RN). However, the behavior of [ 18 F]-fluciclovine PET in newly identified intracranial contrast-enhancing lesions, particularly at initial presentation, remains unclear. OBSERVATIONS A 57-year-old man developed a new ring-enhancing lesion in the left frontal lobe 4.5 years after proton therapy for ethmoid sinus carcinoma. MRI demonstrated progressive enlargement of the lesion over 4 months. [ 18 F]-Fluciclovine PET showed moderate uptake (maximum standardized uptake value [SUV ] 2.96) with a markedly elevated tumor-to-background ratio (TBR 22.77), raising concern for a high-grade glioma. Resection was performed; however, histopathological and molecular analyses confirmed RN. LESSONS This rare case highlights an important diagnostic pitfall in which [ 18 F]-fluciclovine PET demonstrates markedly elevated TBR despite only moderate SUV in RN. Discordant findings between SUV and TBR should be interpreted cautiously, as they may not always indicate active tumor. Careful integration of clinical course, longitudinal imaging findings, and treatment history is important for appropriate clinical decision-making. https://thejns.org/doi/10.3171/CASE26222

Subjects

Author keywords

[18F]-fluciclovineglioblastomapositron emission tomographyradiation necrosistumor-to-background ratio

Authors and institutions

  • Department of Neurosurgery, Kyoto Prefectural University of Medicine, Kyoto.
  • Department of Neurosurgery, Japanese Red Cross Kyoto Daini Hospital, Kyoto.
  • Department of Radiology, Kyoto Prefectural University of Medicine, Kyoto, Japan.

ORCID profiles: Seisuke Tanigawa, Takanari Okamoto, Ichita Taniyama, Takumi Yamanaka, Sachimi Yamada

Cite

APA

Kamata, K., Tanigawa, S., Takeuchi, Y., Okamoto, T., Taniyama, I., Takeuchi, H., Yamanaka, T., Aibe, N., Yamada, S., Yamada, K., & Hashimoto, N. (2026). Unexpected [18F]-fluciclovine hyperuptake in radiation necrosis after proton therapy: illustrative case. Journal of Neurosurgery: Case Lessons, 11(21). https://doi.org/10.3171/case26222

Vancouver

Kamata K, Tanigawa S, Takeuchi Y, Okamoto T, Taniyama I, Takeuchi H, et al. Unexpected [18F]-fluciclovine hyperuptake in radiation necrosis after proton therapy: illustrative case. Journal of Neurosurgery: Case Lessons. 2026;11(21). doi:10.3171/case26222

BibTeX
@article{Kamata2026,
  author = {Kamata, Kazuaki and Tanigawa, Seisuke and Takeuchi, Yasuhiro and Okamoto, Takanari and Taniyama, Ichita and Takeuchi, Hayato and Yamanaka, Takumi and Aibe, Norihiro and Yamada, Sachimi and Yamada, Kei and Hashimoto, Naoya},
  title = {Unexpected [18F]-fluciclovine hyperuptake in radiation necrosis after proton therapy: illustrative case},
  journal = {Journal of Neurosurgery: Case Lessons},
  year = {2026},
  volume = {11},
  number = {21},
  doi = {10.3171/case26222}
}
Start for free →